All Study Flyer
Research that Makes a Difference
The UC Davis MIND Institute supports critical research designed to understand the causes and to develop effective diagnoses, treatments, preventions, and ultimately, cures for neurodevelopmental disorders. Advances in neuroscience, molecular biology, genetics, pharmacology and behavioral sciences are making inroads into understanding brain function. The MIND Institute draws from these and other disciplines to conduct collaborative multidisciplinary research on specific neurodevelopmental disorders, including autism Spectrum Disorders, Down Syndrome, Fragile X Syndrome, Attention-Deficit/Hyperactivity Disorder (ADHD) and Chromosome 22q11.2 Deletion Syndrome.
The MIND Institute is uniquely positioned to take advantage of the outstanding expertise at UC Davis. The university offers robust programs in biological, environmental, medical and toxicological sciences.
The scope and impact of the Institute’s Research Program is exceptional. Studies ranging from basic biological studies to treatment trials, have lead to important contributions in such areas as synapse formation and plasticity, biomarkers research, evaluating startle responses, mouse model for autism, gene therapy of the brain, functions of the fragile X and MeCP2 genes, brain structure and the epidemiology of autism.
Highlighted Study of the Month
(MINT) Mapping Impulsivity’s Neurodevelopmental Trajectories
The goal of this longitudinal study is to characterize typical neurodevelopment of cognitive control and reward related function during adolescence and early adulthood and assess its relationship with self‐control in ADHD and typicals. It will also track how underlying behaviors associated with self‐control and impulsivity are associated with academic and educational performance. fMRI, behavioral and educational assessments will be used.
This is an investigator‐initiated study funded by National Institutes of Health. The study consists of a screening phase and data collection phase. Appointments will include a baseline assessment, and follow‐ups occurring at approximately 12, 24, 36 and 48 months. Study visits may consist of collection of demographic information and past medical history, urine testing, rating scales, IQ testing behavioral testing and fMRI scans.
Child, adolescent and adult males and females ages 12‐25 either typically developing or with a diagnosis of Attention Deficit Hyperactivity Disorder. For more information about this study, contact Erin Calfee or Arthur Hartanto at (916) 703-0294.
Learn more about the MINT study - (click here)